About Ensysce Biosciences, Inc. - Common Stock (ENSC)
Ensysce Biosciences Inc is a biotechnology company focused on developing innovative solutions for the treatment of pain while minimizing the risk of addiction associated with opioid medications. The company utilizes its proprietary drug delivery platforms to create products that can enhance the therapeutic effects of existing pain medications and reduce their potential for misuse. Through advanced research and development, Ensysce aims to address the growing public health crisis surrounding opioid overuse by providing safer and more effective alternatives for pain management. Read More
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) stock rose
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC) shares
Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)
Investor interest in low-priced growth stocks continues to build as companies across defense technology, artificial intelligence, biotechnology, digital media, and cross-border logistics announce significant business developments. Several stocks trading below the $1 level are attracting increased attention after releasing catalysts that could drive investor interest in the weeks ahead.
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings (NASDAQ:ADGM) stock
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics (NASDAQ:RNAZ)
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
